
Thursday, November 01, 2018 9:53:35 AM
A major paper on sleep disorders in the U.S. makes these important points:
The International Classification of Sleep Disorders distinguishes more than 80 different disorders, which can be effectively treated. Problems with falling asleep or daytime sleepiness affect approximately 35 to 40% of the U.S. adult population annually and are a significant cause of morbidity and mortality. However, the prevalence, burden, and management of sleep disorders are often ignored or overlooked by individuals and society in general. This leads to an underappreciation and undertreatment of sleep disorders, making this group of illnesses a serious health concern.
https://www.researchgate.net/publication/11298507_The_Prevalence_Cost_Implications_and_Management_of_Sleep_Disorders_An_Overview
Ok, so at least a third of American adults have sleep disorders that, “...are a significant cause of morbidity and mortality.”
A far bigger problem than generally recognized — with profound societal implications.
What if most of the Anavex 2-73-dosed Alzheimer’s patients in the upcoming clinical trial start to sleep soundly? (Or, just a third?) Will anything by anyone be made of that?
(For those unfamiliar with the matter, restoration of normal sleep patterns for many was an unexpected finding in the Phase 1 Anavex 2-73 safety and tolerability study for Alzheimer’s patients. Sleep deprivation is a major, complicating symptom of Alzheimer’s disease, currently with no effective treatment.)
Volume: | 697,761 |
Day Range: | 8.57 - 9.07 |
Bid: | 8.77 |
Ask: | 8.98 |
Last Trade Time: | 6:10:05 PM EDT |
Total Trades: | 7,124 |
Recent AVXL News
- Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease • GlobeNewswire Inc. • 04/05/2025 03:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:46:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2025 01:45:40 AM
- Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2025 11:30:00 AM
- Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference • GlobeNewswire Inc. • 02/24/2025 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2025 02:06:26 PM
- Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/12/2025 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 • GlobeNewswire Inc. • 02/05/2025 12:30:00 PM
- Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio • GlobeNewswire Inc. • 01/27/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2025 02:12:55 AM
- Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease • GlobeNewswire Inc. • 01/15/2025 12:30:00 PM
- New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients • GlobeNewswire Inc. • 01/13/2025 12:30:00 PM
- Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/06/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/24/2024 12:00:31 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/23/2024 09:30:33 PM
- Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 12/23/2024 12:30:00 PM
- Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease • GlobeNewswire Inc. • 12/23/2024 12:00:00 PM
- Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024 • GlobeNewswire Inc. • 12/16/2024 12:30:00 PM
- Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference • GlobeNewswire Inc. • 12/09/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/07/2024 02:00:08 AM
- Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024 • GlobeNewswire Inc. • 12/02/2024 12:30:00 PM
- Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA • GlobeNewswire Inc. • 11/26/2024 12:30:00 PM
- Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal • GlobeNewswire Inc. • 11/25/2024 12:30:00 PM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM
Opus Holdings, Inc. (OTC: CATV) Reports Nearly $500K in Q4 Revenue, eliminates $830K in Debt, and Appoints Visionary CEO to Lead Bold Transformation • CATV • Apr 10, 2025 9:34 AM
AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge • NGTF • Apr 10, 2025 9:00 AM
UAV Corp Powers Forward: T-Wing Nears Completion, Global Momentum Accelerates with Saudi Arabia in Sight • UMAV • Apr 10, 2025 8:30 AM
UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology, Genetic Networks Signs MOU with UMAV • FITY • Apr 9, 2025 9:00 AM